Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Birinapant||TL32711||SMAC Mimetic 8||TL32711 (birinapant) is a a bivalent SMAC-mimetic compound, which binds to and inhibits Inhibitor of Apoptosis proteins (IAPs), leading to tumor cell death (PMID: 24563541, PMID: 26566079).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lymphoma||not applicable||Birinapant||Phase I||Actionable||In a Phase I dose escalation study of birinapant, 50 patients with advanced solid tumors or lymphoma were enrolled and no patients achieved complete or partial remission (PMID: 26333381).||26333381|
|Unknown unknown||Advanced Solid Tumor||not applicable||Birinapant||Phase I||Actionable||In a Phase I dose escalation study of birinapant, 50 patients with advanced solid tumors or lymphoma were enrolled and no patients achieved complete or partial remission while stable disease was observed in 3 patients (PMID: 26333381).||26333381|
|PTEN loss||glioblastoma||predicted - sensitive||Birinapant||Preclinical - Cell culture||Actionable||In a preclinical study, TL32711 (birinapant) treatment inhibited proliferation of PTEN-deficient glioblastoma cells in culture (PMID: 32737157).||32737157|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03803774||Phase I||Birinapant||Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma||Recruiting||USA||0|
|NCT01940172||Phase I||Conatumumab Birinapant||Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer||Completed||USA||0|